Q32 Bio presents SIGNAL-AA trial results at EADV Congress 2026

Q32 Bio said it presented results from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata in a late-breaker at the European Academy of Dermatology and Venereology Congress 2026.